Top

Published in:

01-08-2018 | Research Paper

Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials

Authors: Mark B. Faries, Dale Han, Michael Reintgen, Lauren Kerivan, Douglas Reintgen, Corrado Caracò

Published in: Clinical & Experimental Metastasis | Issue 5-6/2018

Abstract

While there is no doubt that regional lymph node metastases are an enormously important factor in melanoma staging and treatment, the biology behind this significance and its precise implications for treatment planning have been a leading controversy in melanoma and other solid tumors for over a century. Recent clinical data, including data from prospective randomized clinical trials have refined our understanding of the process of nodal metastases and the advantages and disadvantages of different clinical management strategies. This review presents two points of view in this debate and discusses the results of new data analyses as well as pivotal clinical trials informing the discussion.

Snow HM (1892) Melanotic cancerous disease. Lancet 140:869–922CrossRef

Bodenham DC (1968) A study of 650 observed malignant melanomas in the South-West region. Ann R Coll Surg Engl 43:218–239PubMedPubMedCentral

SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/melan.html. Accessed 2 Jan 2018

Fisher B, Fisher ER (1966) Transmigration of lymph nodes by tumor cells. Science 152:1397–1398CrossRef

Dadras SS, Lange-Asschenfeldt B, Velasco P et al (2005) Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 18:1232–1242CrossRef

Harrell MI, Iritani BM, Ruddell A (2007) Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170:774–786CrossRef

Cochran AJ, Morton DL, Stern S et al (2001) Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 14:604–608CrossRef

Morton DL, Thompson JF, Cochran AJ et al (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1317CrossRef

Veronesi U, Adamus J, Bandiera DC et al (1977) Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297:627–630CrossRef

10.

Veronesi U, Adamus J, Bandiera DC et al (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420–2430CrossRef

11.

Sim FH, Taylor WF, Pritchard DJ et al (1986) Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 61:697–705CrossRef

12.

Cascinelli N, Morabito A, Santinami M et al (1998) Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Program Lancet 351:793–796

13.

Balch C, Soong S, Ross M et al (2000) Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0–4.0 mm). Ann Surg Oncol 7:87–97CrossRef

14.

Morton DL, Thompson JF, Cochran AJ et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 370:599–609CrossRef

15.

Songun I, Putter H, Kranenbarg EM et al (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449CrossRef

16.

Hulscher JB, van Sandick JW, de Boer AG et al (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662–1669CrossRef

17.

Izbicki JR, Passlick B, Pantel K et al (1998) Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg 227:138–144CrossRef

18.

Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318:918–926CrossRef

19.

D’Cruz AK, Vaish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529CrossRef

20.

Balch CM, Cascinelli N, Sim FH (2003) Elective lymph node dissection: Results of prospective randomized surgical trials. In: Balch CM, Houghton AN, Sober AJ et al (eds) Cutaneous melanoma. Quality Medical Publishing, Saint Louis, pp 379–395

21.

Hein DW, Moy RL (1992) Elective lymph node dissection in stage I malignant melanoma: a meta-analysis. Melanoma Res 2:273–277CrossRef

22.

Fisher B (1980) Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 40(11):3863–3874

23.

Hellman S (1994) Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12(10):2229–2234CrossRef

24.

Halsted WS (1894) I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 20(5):497–555CrossRef

25.

Leong SP, Tseng WW (2014) Micrometastatic cancer cells in lymph nodes, bone marrow, and blood: clinical significance and biologic implications. CA Cancer J Clin 64(3):195–206CrossRef

26.

Cady B (1997) Basic principles in surgical oncology. Arch Surg 132(4):338–346CrossRef

27.

Morton DL, Wen DR, Wong JH et al (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4):392–399CrossRef

28.

Morton DL, Hoon DS, Cochran AJ et al (2003) Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 238(4):538–549; discussion 549–550.PubMedPubMedCentral

29.

Faries MB, Thompson JF, Cochran AJ et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 8(23):2211–2222CrossRef

30.

Leiter U, Stadler R, Mauch C et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17(6):757–767CrossRef

31.

Balch CM, Gershenwald JE, Soong SJ et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 20(36):6199–6206 27(CrossRef

32.

Gershenwald JE, Scolyer RA, Hess KR et al (2017) Melanoma of skin. In: Amin MB, Edge S, Greene F (eds) AJCC cancer staging manual, 8th edn. Springer, New York

33.

Essner R (2003) Surgical treatment of malignant melanoma. Surg Clin N Am 83(1):109–156CrossRef

34.

Lens MB, Dawes M, Goodacre T, Newton-Bishop JA (2002) Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. Arch Surg 137(4):458–461CrossRef

35.

Wong SL, Morton DL, Thompson JF et al (2006) Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13(6):809–816CrossRef

36.

Ross MI, Reintgen DS, Balch CM (1993) Selective lymphadenectomy: the emerging role of lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9:219–223PubMed

37.

Miliotes G, Albertini J, Berman C, Messina J, Glass F, Cruse CW, Rapaport D, Puleo C, Fenske N, Petsoglou C, DeConti R, Lyman G, Reintgen DS (1996) The tumor biology of melanoma nodal metastases. Am Surg 62:81–88PubMed

38.

Balch C, Gershenwald JE, Soong S-J, Thompson J, Byrd D, Cascinelli N, Cochran AJ, Coit D, Eggermont A, Johnson T, Kirkwood J, Leong S, McMasters K, Mihn M, Morton D, Ross M, Sondak V (2010) Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459CrossRef

39.

Balch CM, Soon SJ, Atkins MB et al (2004) An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131–149CrossRef

40.

Reintgen M, Murray L, Akman K, Giuliano R, Loznicki A, Shivers S, Reintgen DS (2013) Evidence for a better nodal staging system for melanoma: The clinical relevance of metastatic disease confined to the sentinel lymph nodes. Ann Surg Oncol 20:668–674CrossRef

41.

Ries LAG, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8(6):541–552CrossRef

42.

Merrill RM, Hunter BD (2010) Conditional survival among cancer patients in the United States. Oncologist 15(8):873–882CrossRef

43.

Kerivan L, Reintgen M, Shivers S, Reintgen E, Reintgen DS (2017) Conditional survival in melanoma: meaningful prognostic information for patients and physicians. Presented at the Society of Surgical Oncology Meeting, March. Seattle, Washington

44.

Faries MB (2018) Completing the dissection in melanoma: increasing decision precision. Ann Surg Oncol. https://doi.org/10.1245/s10434-017-6330-4 Jan 4.CrossRefPubMed

45.

Rossi CR, Mocellin S, Campana LG et al (2018) Prediction of non-sentinel node status in patients with melanoma and positive sentinel node biopsy: an Italian Melanoma Intergroup (IMI) Study. Ann Surg Oncol 25:271–279CrossRef

Title: Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials
Authors: Mark B. Faries
Dale Han
Michael Reintgen
Lauren Kerivan
Douglas Reintgen
Corrado Caracò
Publication date: 01-08-2018
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 5-6/2018
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-018-9898-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5-6/2018

Future perspectives: cancer metastases

Genetics of metastasis: melanoma and other cancers

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

Metastatic gynecologic malignancies: advances in treatment and management

Cancer initiation and progression within the cancer microenvironment

The role of radiation therapy in the treatment of metastatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer